Details

Autor(en) / Beteiligte

• Krause, Philip
• Fleming, Thomas R
• Longini, Ira
• Henao-Restrepo, Ana Maria
• Peto, Richard
• Dean, NE
• Halloran, ME
• Huang, Y
• Fleming, TR
• Gilbert, PB
• DeGruttola, V
• Janes, HE
• Krause, PR
• Longini, IM
• Nason, MC
• Peto, R
• Smith, PG
• Riveros, AX
• Gsell, PS
• Henao-Restrepo, AM

Titel

COVID-19 vaccine trials should seek worthwhile efficacy

Ist Teil von

• The Lancet (British edition), 2020-09, Vol.396 (10253), p.741-743

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• [...]the initial trials comparing COVID-19 vaccines versus placebo should seek reliable evidence not only of some efficacy but of worthwhile efficacy. [...]although efficacy far greater than 50% would be better, efficacy of about 50% would represent substantial progress. Evaluation of multiple COVID-19 vaccines with standardised methodology will facilitate regulatory and deployment decisions.7 Unless such decisions are informed by reliable randomised evidence, the effect on public acceptance of COVID-19 vaccines could adversely affect COVID-19 control and the uptake of vaccines against other diseases.8 The WHO Solidarity Vaccines Trial9 (figure) aims to evaluate efficiently and rapidly (within 3–6 months of each vaccine's introduction into the study) the efficacy of multiple vaccines,10 helping to ensure that weakly effective vaccines are not deployed.